Kenneth M. Liebman, MD, FACS
Director, Neurosurgical Critical Care, Cerebrovascular & Endovascular Neurosurgery, Stroke & Cerebrovascular Center of New Jersey
Dr. Kenneth Liebman serves as director of Neurosurgical Critical Care at Capital Health. After completing his neurosurgery residency at Thomas Jefferson University Hospital, Dr. Liebman was director of cerebrovascular neurosurgery for the Department of Neurosciences at Seton Hall University. He was chief of the Division of Neurosurgery at Muhlenberg Hospital prior to joining the medical staff at Thomas Jefferson University Hospital, where he received fellowship training in cerebrovascular microsurgery and interventional endovascular neurosurgery. As an assistant professor of neurosurgery at Thomas Jefferson University's Jefferson Medical College, he started and directed a microvascular course taught to residents and fellows.
As part of the Institute for Neurosciences research program at Capital Health, Dr. Liebman is an investigator on numerous clinical trials focusing on stroke and aneurysm. Dr. Liebman was the first physician in the country to treat a patient using TREVO™, a new, investigational device for the removal of clots in ischemic stroke patients. He was also one of the first in the Philadelphia region to use Solitaire™ another investigational clot retrieval device. In addition, Dr. Liebman was among the first in the region to use the Merci Retriever and Penumbra devices as well as the Cordis Enterprise Stent.
Dr. Liebman is also trained in the use of the CyberKnife® Robotic Radiosurgery System, providing patients with a non-invasive treatment option for AVMs, brain and spinal tumors, and trigeminal neuralgia.
A nationally recognized academic leader in the area of cerebrovascular care, Dr. Liebman has written chapters and numerous articles in various publications and peer reviewed journals that are used as data for colleagues across the country and he lectures at international conferences for physicians around the world. He has been recognized with multiple awards by both patients and peers.
Arlan H. Mintz, MD, MSc, FRCS (C), FACS
Surgical Director, CyberKnife, Capital Health
Dr. Mintz, director of Neuro-Oncology and surgical director of CyberKnife at Capital Health, joined the healthcare system’s Capital Institute for Neurosciences from the University of Pittsburgh where he was an associate professor of Neurological Surgery and Radiation Oncology at the University of Pittsburgh School of Medicine and director of University of Pittsburgh Medical Center’s Adult Neurosurgical Oncology Program.
Dr. Mintz is board certified in neurological surgery in both the United States and Canada and specializes in the treatment of brain and spine tumors. He treats patients with both primary tumors, benign and malignant in nature, and metastatic brain tumors which are the result of cancer that has spread from another location in the body. In determining surgical options for his patients, Dr. Mintz offers comprehensive treatment options including awake craniotomies using cortical mapping, minimally invasive approaches removing tumors with the least amount of disruption to surrounding brain tissue by using endoscopic and microscopic port surgery, and non-invasive radiosurgery using CyberKnife® and TrueBeam™.
While at the University of Pittsburgh, Dr. Mintz served as training program director for the minimally invasive neurosurgery center and established an international fellowship program. He was an instructor in courses on Trilogy and True Beam radiosurgery and led the CyberKnife neurosurgical program to achieve status as the world’s most active CyberKnife.
Dr. Mintz has published numerous academic basic science and clinical research articles and has lectured internationally and nationally in addition to being an active researcher in the area of brain tumors.
Dr. Mintz completed his undergraduate education at the University of Toronto with a Bachelor of Science specialist degree in neurosciences. Dr. Mintz then completed his Master of Science degree in neurophysiology at the University of Toronto, the findings of which were published in Science. He then received his medical degree from McMaster University in Ontario, Canada. During his residency, Dr. Mintz also completed an additional Master of Science degree in clinical epidemiology and clinical trial design, also at McMaster University.
Following his residency, Dr. Mintz joined the faculty at McMaster University where he held the position of clinical assistant professor in neurosurgery and where he served as chair of the Neuro-Oncology Disease Site Group at Hamilton Regional Cancer Center. Following his tenure at McMaster University, Dr. Mintz joined Trillium Hospital in Toronto where he developed an Awake Craniotomy Program and led the hospital’s neuro-oncology program.
While in Canada, Dr. Mintz previously served as chair of the Ontario Medical Associations’ Section of Neurosurgery. He was the lead author on the largest randomized controlled trial examining the role of surgery and radiation in the treatment of brain metastasis. Dr. Mintz was also a member of the Neuro-Oncology Practice Guideline Committee for Cancer Care Ontario and was the lead author on the Brain Metastasis and Gliadel Wafer Practice Guidelines. He is also a former board member of the Specialist Coalition of Ontario.
Dr. Mintz is a fellow of the American College of Surgeons. He is a member of the Congress of Neurological Surgeons Tumor Section, the Society of Neuro-Oncology, the North American Skull Base Society, CyberKnife Society, the Radiation Therapy Oncology Group, International Stereotactic Radiosurgery Society, and the Royal College of Physicians and Surgeons of Canada.